![SCOTUS Won’t Weigh in on How Whistleblowers Make Valid FCA Claims](https://www.g2intelligence.com/wp-content/uploads/2022/09/Oct22.NLR_.WhistleblowersCasetoSupCt-iStock-1800x1250-1-1080x675.jpg)
SCOTUS Won’t Weigh in on How Whistleblowers Make Valid FCA Claims
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
How to create a written policy banning retaliation for whistleblowing and for investigating retaliation complaints.
What happens when a compliance officer is the whistleblower in a qui tam retaliation lawsuit?
This month’s key lab cases involve false billing of urine drug and PGx tests and two lawsuits that were tossed.
A recent $3.5 million settlement illustrates the kinds of pitfalls that can result in liability for hospital and freestanding sleep labs.